Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
| Revenue (Most Recent Fiscal Year) | $94.19B |
| Net Income (Most Recent Fiscal Year) | $26.80B |
| PE Ratio (Current Year Earnings Estimate) | 21.40 |
| PE Ratio (Trailing 12 Months) | 22.86 |
| PEG Ratio (Long Term Growth Estimate) | 2.40 |
| Price to Sales Ratio (Trailing 12 Months) | 6.32 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 7.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 17.49 |
| Pre-Tax Margin (Trailing 12 Months) | 34.59% |
| Net Margin (Trailing 12 Months) | 28.46% |
| Return on Equity (Trailing 12 Months) | 33.04% |
| Return on Assets (Trailing 12 Months) | 13.46% |
| Current Ratio (Most Recent Fiscal Quarter) | 1.03 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.77 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.48 |
| Inventory Turnover (Trailing 12 Months) | 2.22 |
| Book Value per Share (Most Recent Fiscal Quarter) | $33.84 |
| Earnings per Share (Most Recent Fiscal Quarter) | $2.46 |
| Earnings per Share (Most Recent Fiscal Year) | $10.79 |
| Diluted Earnings per Share (Trailing 12 Months) | $11.05 |
| Exchange | NYSE |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Common Shares Outstanding | 2.41B |
| Free Float | 2.41B |
| Market Capitalization | $595.03B |
| Average Volume (Last 20 Days) | 8.56M |
| Beta (Past 60 Months) | 0.35 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.16% |
| Percentage Held By Institutions (Latest 13F Reports) | 69.55% |
| Annual Dividend (Based on Last Quarter) | $5.20 |
| Dividend Yield (Based on Last Quarter) | 2.11% |